Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderstichele, Hugo Marcel, Teunissen, Charlotte E., Vanmechelen, Eugeen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908532/
https://www.ncbi.nlm.nih.gov/pubmed/31833029
http://dx.doi.org/10.1007/s40120-019-00166-3
_version_ 1783478744053186560
author Vanderstichele, Hugo Marcel
Teunissen, Charlotte E.
Vanmechelen, Eugeen
author_facet Vanderstichele, Hugo Marcel
Teunissen, Charlotte E.
Vanmechelen, Eugeen
author_sort Vanderstichele, Hugo Marcel
collection PubMed
description This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).
format Online
Article
Text
id pubmed-6908532
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-69085322019-12-26 Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment Vanderstichele, Hugo Marcel Teunissen, Charlotte E. Vanmechelen, Eugeen Neurol Ther Review This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD). Springer Healthcare 2019-12-12 /pmc/articles/PMC6908532/ /pubmed/31833029 http://dx.doi.org/10.1007/s40120-019-00166-3 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Vanderstichele, Hugo Marcel
Teunissen, Charlotte E.
Vanmechelen, Eugeen
Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_full Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_fullStr Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_full_unstemmed Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_short Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
title_sort critical steps to be taken into consideration before quantification of β-amyloid and tau isoforms in blood can be implemented in a clinical environment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908532/
https://www.ncbi.nlm.nih.gov/pubmed/31833029
http://dx.doi.org/10.1007/s40120-019-00166-3
work_keys_str_mv AT vanderstichelehugomarcel criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment
AT teunissencharlottee criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment
AT vanmecheleneugeen criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment

Ejemplares similares